Idorsia Ltd. · SIX:IDIA
Idorsia — Fact Sheet (February 2019)
6 slides from Idorsia's fact sheet, February 2019
Slide 1: Idorsia Company Profile
Idorsia Company Profile Headquartered in Switzerland - a biotech-hub of Europe—Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of over 7
Slide 2: Share Information and Company Strategy
Share Information Company Strategy Idorsia was incorporated in March 2017 We will develop Idorsia into one of Europe’s Become a sustainable company and listed on the SIX Swiss Exchange (ticker leading biopharmaceutical companies, with Idorsia’s highly qualified professionals aim symbol: IDIA) in Jun
Slide 3: Clinical Development Pipeline
Clinical Development Pipeline Compound Mechanism of Action Target Indication Status ACT-541468 Dual orexin receptor antagonist Insomnia Phase 3 Aprocitentan* Dual Endothelin receptor antagonist Resistant hypertension management Phase 3 Clazosentan** Endothelin receptor antagonist Vasospasm associate
Slide 4: Partnerships
Partnerships Collaboration Agreement Collaboration Agreement with Roche Revenue Sharing Agreement with Janssen Biotech In December 2017, Idorsia entered into a with Johnson & Johnson In December 2017, Janssen Biotech, Inc. research collaboration that provides Roche Idorsia Pharmaceuticals Ltd, J&J a
Slide 5: Company milestones
Company milestones 2017 2018 2019 March May February Incorporation of Idorsia Phase 3 registration study with lucerastat Phase 3 registration program with for patients with Fabry disease initiated clazosentan for patients with cerebral June vasospasm associated with aSAH initiated Listing of Idorsia
Slide 6: Idorsia is an independent biopharmaceutical company
Idorsia is an independent biopharmaceutical company based on science and innovation. The company is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. It is headquartered in Allschwil/Basel, Switzerland and is quoted on the SIX Swiss Exc